Does Slower AMDS Uptake Recast Artivion’s Core Growth Narrative (AORT)

Simply Wall St.07-23

Earlier in 2026, Artivion reported first-quarter results that were broadly in line with expectations but reduced its full-year outlook after slower-than-anticipated starter set sales for its AMDS ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2653715852?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2026-07-23 11:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653715852","market":"nz","top_or_hot":-1,"title":"Does Slower AMDS Uptake Recast Artivion’s Core Growth Narrative (AORT)","media":"Simply Wall St.","content":"<div>\n<p>Earlier in 2026, Artivion reported first-quarter results that were broadly in line with expectations but reduced its full-year outlook after slower-than-anticipated starter set sales for its AMDS ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/does-slower-amds-uptake-recast-artivions-core-growth-narrati\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Does Slower AMDS Uptake Recast Artivion’s Core Growth Narrative (AORT)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDoes Slower AMDS Uptake Recast Artivion’s Core Growth Narrative (AORT)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-23 11:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/does-slower-amds-uptake-recast-artivions-core-growth-narrati><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier in 2026, Artivion reported first-quarter results that were broadly in line with expectations but reduced its full-year outlook after slower-than-anticipated starter set sales for its AMDS ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/does-slower-amds-uptake-recast-artivions-core-growth-narrati\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/does-slower-amds-uptake-recast-artivions-core-growth-narrati","article_id":"2653715852","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-aort/artivion/news/does-slower-amds-uptake-recast-artivions-core-growth-narrati","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2653715852","pubTimestamp":1784777468,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier in 2026, Artivion reported first-quarter results that were broadly in line with expectations but reduced its full-year outlook after slower-than-anticipated starter set sales for its AMDS aortic device, despite reporting a 12% non-GAAP constant currency revenue increase.\nThis combination of solid headline growth with softer uptake of a key new product highlights how execution on AMDS adoption is central to Artivion’s growth story.\nWe’ll now examine how the lowered full-year outlook...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","AMDS":"GRANITESHARES 1X SHORT AMD DAILY ETF","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","AORT":"Artivion"},"translate_title":"AMD 吸收放缓是否会重塑 Artivion 的核心增长叙事（AORT）","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AORT":1.5,"AMDS":0.9},"content_text":"Earlier in 2026, Artivion reported first-quarter results that were broadly in line with expectations but reduced its full-year outlook after slower-than-anticipated starter set sales for its AMDS aortic device, despite reporting a 12% non-GAAP constant currency revenue increase. This combination of solid headline growth with softer uptake of a key new product highlights how execution on AMDS adoption is central to Artivion’s growth story. We’ll now examine how the lowered full-year outlook tied to slower AMDS starter set sales affects Artivion’s broader investment narrative. We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.AdvertisementArtivion Investment Narrative RecapTo own Artivion, you need to believe that its specialized aortic and valve portfolio can compound value as newer devices like AMDS gain broader adoption. The recent guidance cut tied to slower AMDS starter set sales directly affects that near term AMDS adoption catalyst and reinforces the biggest current risk: dependence on a small set of premium, complex products gaining traction fast enough to support growth. The most relevant update here is the FDA’s June 2026 PMA approval for AMDS, which expands its use beyond the prior HDE framework into a roughly US$150 million U.S. annual market opportunity. That approval underpins the core growth thesis for AMDS, but the slower than expected starter set uptake in Q1 suggests the ramp may be more gradual than the more optimistic expectations that were embedded in earlier outlooks. Yet investors should also be aware that if AMDS adoption continues to lag expectations in a market this concentrated, the risk profile could shift materially over time for... Read the full narrative on Artivion (it's free!)Artivion's narrative projects $619.8 million revenue and $44.7 million earnings by 2029. This requires 10.6% yearly revenue growth and a $33.0 million earnings increase from $11.7 million today.Uncover how Artivion's forecasts yield a $42.00 fair value, a 67% upside to its current price.Exploring Other PerspectivesAORT 1-Year Stock Price Chart Some of the most optimistic analysts were assuming revenue could reach about US$650.4 million and earnings around US$49.3 million by 2029, which is a much bolder view than consensus and could prove too optimistic if high priced products like AMDS, NEXUS and Arcevo LSA face slower adoption after this guidance cut.Explore 2 other fair value estimates on Artivion - why the stock might be worth as much as 67% more than the current price!Form Your Own VerdictDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Artivion research is our analysis highlighting 3 key rewards that could impact your investment decision.Our free Artivion research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Artivion's overall financial health at a glance.Seeking Other Investments?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:Uncover the next big thing with 21 elite penny stocks that balance risk and reward.This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2653715852","isCrawlerRequest":true}